

Managing Off-Label Use of Steroids: Ethical and Legal Guidelines for Practitioners

Bizimana Rukundo T.

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

Off-label steroid use in clinical practice raises significant ethical, legal, and safety challenges, particularly in areas like rheumatology, sports medicine, and dermatology. While such use may offer therapeutic benefits in conditions beyond approved indications, it also poses risks related to patient safety, informed consent, misuse, and potential legal consequences. This review explores the complexities surrounding off-label steroid prescriptions, including the regulatory frameworks that govern their use, the ethical considerations involved, and the responsibilities of healthcare practitioners in ensuring patient safety. By examining best practices, clinical guidelines, and case studies, the review provides a comprehensive framework for responsible prescribing, emphasizing the need for clear protocols, enhanced monitoring, and education for both practitioners and patients. Ultimately, it calls for improved regulations and a more ethical approach to the off-label use of steroids to ensure patient protection and prevent misuse.

Keywords: Off-label use, steroids, ethical prescribing, informed consent, patient safety.

INTRODUCTION

The off-label use of steroids in medical practice is a topic of considerable debate, touching on critical ethical, legal, and clinical considerations. While steroids are widely used for their anti-inflammatory and immunosuppressive properties, their application beyond approved indications presents unique challenges for healthcare practitioners [1]. Off-label use refers to the prescription of medications for conditions, patient populations, dosages, or durations that have not been officially sanctioned by regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) [2]. Although off-label prescribing is a common and sometimes necessary aspect of medical practice, the use of steroids in this context raises concerns regarding patient safety, informed consent, potential misuse, and legal accountability [3].

The off-label use of steroids in medical practice is a contentious issue that raises concerns about patient safety, informed consent, potential misuse, and legal accountability. Steroids are commonly prescribed for conditions such as chronic pain, respiratory diseases, dermatological disorders, and in sports medicine for performance enhancement or injury recovery. However, these uses may lack sufficient scientific evidence, creating a precarious situation where the benefits and risks are not well understood. Inadequate regulation and oversight of off-label steroid use have

led to cases of misuse, adverse effects, and even malpractice lawsuits [4]. Furthermore, ethical concerns arise when patients are not adequately informed about the off-label nature of their treatment, potentially leading to violations of autonomy and informed consent principles. The absence of standardized guidelines for off-label steroid prescribing exacerbates these risks, leaving practitioners vulnerable to legal challenges and patients at risk of harm [5]. Addressing these issues requires a comprehensive examination of the ethical and legal frameworks governing off-label steroid use, as well as the development of clear guidelines for responsible prescribing practices. This study aims to explore the ethical and legal challenges associated with the off-label use of steroids and provide healthcare practitioners with a structured framework for responsible prescribing [6]. It examines the prevalence and scope of off-label steroid use in various medical specialties, analyzes the ethical implications of prescribing steroids off-label, evaluates the legal frameworks governing off-label prescriptions, explores case studies and clinical guidelines that highlight best practices for off-label steroid use while ensuring patient safety, and proposes recommendations for improving regulatory oversight, practitioner education, and patient awareness regarding off-label steroid use. This study

holds significant implications for multiple stakeholders, including healthcare practitioners, policymakers, patients, and regulatory agencies. Understanding the ethical and legal dimensions of off-label steroid use is crucial for ensuring patient safety, reducing medical malpractice risks, and fostering a more transparent healthcare system. For healthcare practitioners, this review provides a structured approach to navigating the complexities of off-label steroid prescribing, outlining ethical principles and legal responsibilities, equipping medical professionals with the knowledge needed to make informed decisions while minimizing the risk of legal repercussions. For patients, this study emphasizes the importance of patient education and informed consent, ensuring that individuals receiving off-label steroid treatments are fully aware of potential risks and benefits. Increased transparency in prescribing practices can help build trust between patients and healthcare providers, leading to better treatment adherence and outcomes. The off-label use of steroids is a prevalent yet controversial aspect of medical practice that requires careful consideration of ethical, legal, and clinical factors. By examining best practices, legal frameworks, and ethical considerations, this review advocates for enhanced guidelines, improved practitioner education, and stronger regulatory oversight to ensure that off-label steroid use is both safe and ethically sound.

Regulatory and Legal Considerations

Off-label steroid use, which involves prescribing steroids beyond their approved indications, is a complex issue governed by regulatory guidelines, legal considerations, and institutional policies. The FDA, EMA, and WHO provide frameworks for drug approval, safety monitoring, and enforcement of proper medical use [7]. The FDA does not regulate the practice of medicine, meaning physicians can prescribe steroids at their discretion. However, pharmaceutical companies cannot market or promote steroids for off-label uses unless they undergo additional approval processes. The EMA regulates drug approvals across EU member states but allows national health authorities to decide on off-label prescribing policies. Some EU countries restrict off-label steroid use unless alternative treatments have failed. The WHO emphasizes pharmacovigilance to monitor adverse effects and combat unethical prescribing. Physicians who prescribe steroids off-label may face legal challenges, including malpractice lawsuits, regulatory sanctions, insurance and reimbursement issues, and pharmaceutical marketing violations. Medical boards and health authorities can investigate and penalize doctors who prescribe steroids recklessly or without proper documentation, with penalties including license suspension, fines, or criminal charges in severe cases [8]. Healthcare

institutions and professional bodies implement policies to ensure responsible steroid prescribing, such as hospital and institutional oversight, medical ethics committees, continuing medical education (CME), and prescription drug monitoring programs (PDMPs). Physicians must do so responsibly, ensuring their decisions are supported by scientific evidence, ethical standards, and legal compliance.

Ethical Considerations in Off-Label Steroid Use

Off-label steroid use presents both opportunities and ethical dilemmas. The principle of beneficence in medical ethics requires healthcare providers to act in the best interest of their patients, aiming to maximize benefits while minimizing harm [9]. Off-label steroid use may provide relief for autoimmune disorders, chronic inflammatory conditions, or rare diseases, and may lead to groundbreaking medical advancements. However, there are risks such as lack of regulatory oversight, steroid dependence and misuse, and potential healthcare inequities. Physicians must carefully weigh these risks against the potential benefits, ensuring informed consent is scientifically justified. Informed consent is crucial in ethical medical practice, particularly when prescribing medications off-label [10]. Physicians should provide clear, evidence-based information about the uncertainty surrounding off-label steroid use, give patients adequate time and support to make an informed decision, and obtain written consent. Addressing conflicts of interest and pharmaceutical influences is essential, as financial relationships between doctors and drug manufacturers can create biases, distortion of medical research, and erode patient trust. To mitigate conflicts of interest, physicians should disclose financial ties, drive clinical decisions by peer-reviewed research, medical guidelines, and patient needs, and enforce policies that prevent undue pharmaceutical influence.

Clinical and Safety Implications

Off-label steroid use has both therapeutic potential and inherent risks, making it crucial to assess its clinical safety and effectiveness. While steroids can offer relief in cases where approved treatments fail, improper use can lead to severe side effects, long-term complications, and ethical concerns [11]. Clinicians should evaluate off-label steroid use based on the severity of the condition, availability of approved alternatives, scientific evidence, and patient-specific factors. To monitor patient outcomes and prevent adverse effects, physicians must implement strict monitoring protocols. Key strategies for monitoring and risk prevention include baseline health assessments, dose optimization and tapering, regular laboratory monitoring, patient education and adherence support, and a multi-disciplinary approach. Case studies of successful and problematic off-label steroid use provide valuable insights into the benefits

and risks of off-label steroid use. Successful off-label use, such as dexamethasone for severe COVID-19, have led to medical breakthroughs, while problematic off-label use, such as anabolic steroids for muscle growth, has led to serious side effects and strict legal restrictions [12]. Ethical dilemmas, such as prednisone for chronic fatigue syndrome, have led to mixed recommendations from medical societies. Off-label steroid use presents significant clinical and safety challenges, requiring a rigorous evaluation of risks and benefits. By adopting evidence-based monitoring strategies, prioritizing patient safety, and learning from real-world case studies, clinicians can navigate the complexities of off-label steroid use responsibly.

Practitioner Responsibilities and Best Practices

Off-label prescribing, particularly for steroids, has significant ethical, clinical, and legal implications. Healthcare providers must adhere to best practices and professional guidelines to ensure patient safety and responsible use of medical resources [13]. Evidence-based decision-making (EBDM) is crucial in guiding off-label prescriptions, especially when it comes to the complex and potentially harmful use of steroids. Key elements of EBDM include clinical research and data, clinical judgment, regular risk-benefit analysis, and shared decision-making. Professional organizations play a critical role in setting ethical standards for off-label drug use. They establish ethical guidelines for off-label use, which often emphasize patient safety and well-being, clear criteria for when off-label use is appropriate, transparency and informed consent, and monitoring outcomes and therapy adjustments [14]. Continuing education programs are offered by many organizations to keep practitioners informed about emerging research, guidelines, and regulatory changes. Educating patients about the potential benefits and risks of off-label steroid use is paramount in ensuring they can make informed decisions regarding their treatment. Effective patient education involves clear and transparent communication, highlighting uncertainty and risk, encouraging active participation in treatment decisions, providing written materials or access to reliable online resources, and using shared decision-making tools. Practitioners have an essential responsibility to approach off-label steroid use with careful deliberation, evidence-based practice, and a strong commitment to ethical standards [15]. Following established guidelines and consulting professional

Off-label steroid use presents significant ethical and legal challenges, primarily related to patient safety, informed consent, and the potential for misuse or overuse. The ethical dilemma centers on balancing the potential benefits of off-label steroids with the

organizations can help maintain high standards of care while ensuring patient safety. Educating patients and fostering shared decision-making allows individuals to play an active role in their treatment, aligning treatment choices with their values and understanding of potential risks and benefits. By adhering to these best practices, practitioners can mitigate the risks associated with off-label steroid prescriptions and enhance overall patient outcomes [16].

Future Directions and Policy Recommendations

The growing use of off-label steroid use in medical practice necessitates addressing ethical, clinical, and regulatory challenges. The future of off-label steroid prescribing depends on ensuring patient safety, improving clinical practices, and mitigating risks associated with improper or overuse. Key areas for standardization include developing clear indication guidelines, establishing standard dosing schedules and protocols for managing steroid use in off-label contexts, ensuring patient monitoring and follow-up protocols, and mandating clear and uniform protocols for obtaining informed consent across healthcare systems [17]. Enhancing practitioner training on ethical and legal responsibilities is crucial to ensure they are well-equipped to make informed and ethical decisions. Training should emphasize the ethical principle of beneficence, ensuring that steroids are prescribed in a manner that maximizes patient benefit while minimizing harm. Legal responsibilities and informed consent should be provided, including the potential risks of legal action if off-label steroid use leads to harm. Policy reforms are needed to ensure the ethical and safe use of off-label steroids, mitigate the potential for abuse, and protect vulnerable populations. Governments, regulatory bodies, and healthcare institutions must work together to create regulations that address these issues comprehensively [18]. Key areas for policy reform include stricter regulatory oversight and reporting, development of national guidelines, enhanced surveillance and audit systems, public awareness campaigns and education, and addressing potential abuse in vulnerable populations. As off-label steroid use continues to grow, future policy reforms and standardized protocols are essential to safeguard patient health and reduce potential abuse. By addressing these challenges, the future of off-label steroid use can be more effective and safer for patients.

CONCLUSION

inherent risks of harm, including adverse effects and long-term complications. Legal concerns revolve around the liability associated with prescribing steroids beyond approved indications, especially if patients experience harm. Practitioners must

navigate these complexities by adhering to evidence-based guidelines, maintaining transparency with patients, and ensuring that treatment decisions are rooted in both scientific research and ethical considerations. Healthcare practitioners play a critical role in responsible prescribing by educating patients, obtaining thorough informed consent, and continuously monitoring outcomes to mitigate risks. Their responsibility extends to understanding both the legal frameworks that govern off-label use and the ethical obligations they uphold in prioritizing patient

well-being. This requires a commitment to continuous education and active participation in professional organizations that set ethical standards for practice. To ensure safer and more ethical off-label steroid use, there is a call for improved regulations, including standardized protocols and enhanced monitoring systems. Increased awareness about the risks, supported by better training for practitioners and public education campaigns, is essential for minimizing abuse and promoting patient safety in the use of off-label steroids.

REFERENCES

1. Young, A., Marsh, S.: Steroid use in critical care. *BJA Educ.* 18, 129–134 (2018). <https://doi.org/10.1016/j.bjae.2018.01.005>
2. Van Norman, G.A.: Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities. *JACC: Basic to Translational Science.* 8, 224–233 (2023). <https://doi.org/10.1016/j.jacbts.2022.12.011>
3. Zubair M. F, Oladosu I A, Olawore N O, Usman L A, Fakunle C O, Hamid A A, Ali M S (2011). Bioactive steroid from the root bark of *Psorospermum corymbiferum*. *Chinese Journal of Natural Medicines*, 9, (4), 264–266. [https://doi.org/10.1016/S1875-5364\(11\)60062-9](https://doi.org/10.1016/S1875-5364(11)60062-9)
4. Wenbo, Z., Yan, Z.: The Uses of Anabolic Androgenic Steroids Among Athletes; Its Positive and Negative Aspects- A Literature Review. *J Multidiscip Healthc.* 16, 4293–4305(2023). <https://doi.org/10.2147/JMDH.S439384>
5. Das, A., Panda, S.: Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach. *Indian J Dermatol.* 62, 237–250 (2017). https://doi.org/10.4103/ijd.IJD_169_17
6. Sara, J.D.S., Toya, T., Ahmad, A., Clark, M.M., Gilliam, W.P., Lerman, L.O., Lerman, A.: Mental Stress and Its Effects on Vascular Health. *Mayo Clinic Proceedings.* 97, 951–990(2022). <https://doi.org/10.1016/j.mayocp.2022.02.004>
7. Meadows, W.A., Hollowell, B.D.: ‘Off-label’ drug use: an FDA regulatory term, not a negative implication of its medical use. *Int J Impot Res.* 20, 135–144 (2008). <https://doi.org/10.1038/sj.ijir.3901619>
8. Osama A G, Mohamed A B, Mohamed A F, Ahmed A S, Ahmed B, Mohamed S, Mohamed G. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation Twenty-year experience. *Iranian Journal of Kidney Diseases (IJKD)*, 2, (1), 34–39. (2008).
9. Gavin T, Madeline S, Andrea L H, Jessica A W, Jessica K, Max A, Qing C, Najla E J, Margaret L M, Daniel J W, Bruce R B, Alexander K, Robin R S, Dan K, Shernan G H, Armin R (2021). Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. *British journal of haematology*, 192, 3. (2021). [Dio 10.1111/bjh.17238](https://doi.org/10.1111/bjh.17238)
10. Varkey, B.: Principles of Clinical Ethics and Their Application to Practice. *Med Princ Pract.* 30, 17–28 (2021). <https://doi.org/10.1159/000509119>
11. Sendrasoa, F.A., Ranaivo, I.M., Andrianarison, M., Raharolahy, O., Razanakoto, N.H., Ramarozatovo, L.S., Rapelanoro Rabenja, F.: Misuse of Topical Corticosteroids for Cosmetic Purpose in Antananarivo, Madagascar. *Biomed Res Int.* 2017,9637083(2017). <https://doi.org/10.1155/2017/9637083>
12. Wang, W., Snell, L.B., Ferrari, D., Goodman, A.L., Price, N.M., Wolfe, C.D., Curcin, V., Edgeworth, J.D., Wang, Y.: Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study. *BMC Infectious Diseases.* 22, 776 (2022). <https://doi.org/10.1186/s12879-022-07750-3>
13. Celalettin U, Jacqueline B, Debra A M, Eris T, Marisa M, Armin R, Mallory W, Ece M, Shernan H, Daniel W, Sunita N (2020). Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. *Bone marrow transplantation*, 55, (4), 833–835 (2020).
14. Pugh, J.: Informed Consent, Autonomy, and Beliefs. In: *Autonomy, Rationality, and Contemporary Bioethics* [Internet]. Oxford University Press (2020)

15. AlShareef, S., Gokarakonda, S.B., Marwaha, R.: Anabolic Steroid Use Disorder. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
16. Magnolini, R., Falcato, L., Cremonesi, A., Schori, D., Bruggmann, P.: Fake anabolic androgenic steroids on the black market – a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 22, 1371 (2022). <https://doi.org/10.1186/s12889-022-13734-4>
17. Margaret L M, Shernan G H, Armin R, Todd E D, Claudio G B, John E W, Bruce R

- B, Daniel J W.: Validation of minnesota acute GVHD risk score and identification of new factors associated with initial response to steroids: not all GVHD is created equal. Blood,132,67,(2018). <https://doi.org/10.1182/blood-2018-99-113085>
18. Bates, G., Van Hout, M.-C., Teck, J.T.W., McVeigh, J.: Treatments for people who use anabolic androgenic steroids: a scoping review. Harm Reduction Journal. 16, 75 (2019). <https://doi.org/10.1186/s12954-019-0343-1>

CITE AS: Bizimana Rukundo T.(2025). Managing Off-Label Use of Steroids: Ethical and Legal Guidelines for Practitioners. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(1):49-53. <https://doi.org/10.59298/IDOSRJSR/2024/10.1.49530>